Find policies, billing codes, payers, states, and providers
CPT 81420: Noninvasive Prenatal Sequencing Panel for Chromosomes 13, 18, 21
CPT code 81420 covers a genomic sequencing panel performed on maternal plasma to evaluate circulating cell-free fetal DNA for sequences on chromosomes 13, 18, and 21, used to assess fetal chromosomal aneuploidy noninvasively. This test is an important tool in prenatal screening, informing risk assessment for trisomy 13, 18, and 21 and guiding decisions about diagnostic follow-up. Nationally, such molecular assays have implications for prenatal care pathways, laboratory service demand, and payer coverage policies for genetic screening.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, United Healthcare, and Medicare. Readers will find a concise overview of the code's clinical purpose and typical settings, comparisons to related molecular pathology codes, and discussion of common billing contexts. The publication outlines common diagnostic indications that align with prenatal screening and summarizes related coding that may appear on laboratory service lines. It highlights coverage considerations and coding relationships relevant to laboratory, obstetrics, and genetics providers.
This executive summary is aimed at clinical coders, laboratory billing teams, and payers seeking clear context for CPT code 81420 and what it represents in noninvasive prenatal screening workflows.
Customize your policy alerts
Sign up for cpt 81420 policy alerts
Get alerted when payer policies referencing 81420 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 81420 describes a genomic sequence analysis panel performed on maternal blood to evaluate circulating cell-free fetal DNA for genetic sequences representative of at least the genes on chromosomes 13, 18, and 21. The analysis is intended to detect fetal chromosomal aneuploidy via noninvasive prenatal testing of maternal plasma.
Service type: Genomic sequence analysis / noninvasive prenatal screening (NIPS)
Typical site of service: Clinical laboratory or pathology laboratory, with specimen collection typically occurring in outpatient obstetrics clinics or phlebotomy centers.
National Reimbursement Benchmarks
For CPT 81420 the national commercial landscape centers on a BUCA average of $766.40, with individual commercial payers showing meaningful dispersion in middle-to-upper percentiles. Blue Cross Blue Shield (BCBS) and Cigna exhibit higher median and upper-percentile concentrations, while Aetna and UnitedHealth Group sit lower on median values. BUCA’s quartiles ($524.80 to $847.70) place it near the upper-middle of the payer set, signaling that the average commercial environment for this code is elevated relative to some large national payers.
Examining interquartile dispersion (P75 minus P25) highlights variation in pricing consistency: Blue Cross Blue Shield’s IQR is $228.80, Cigna’s is $595.40, BUCA’s is $322.90, Aetna’s is $299.40, and UnitedHealth Group’s is $370.30. Cigna therefore shows the widest IQR at $595.40, indicating the greatest middle-range variability, while Blue Cross Blue Shield has the tightest IQR at $228.80, indicating comparatively concentrated commercial rates.